The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment

  1. E. Atayik
  2. G. Aytekin

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.reval.2022.06.003
  2. ScreenIT

    SciScore for 10.1101/2022.01.29.22270077: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study was approved by Karatay University Ethics Committee (Decision number 2020/015) Statistical analysis was performed with the IBM SPSS Statistics Version 22 software package.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The study was approved by Karatay University Ethics Committee (Decision number 2020/015) Statistical analysis was performed with the IBM SPSS Statistics Version 22 software package.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    The main limitations of our study are its retrospective design and inclusion of data from single center. Furthermore, especially at the beginning of pandemic, given the fact that rapid tests and PCR tests might not be used sufficiently to detect SARS-CoV-2, this may have caused a lower prevalence of SARS-CoV-2. The age population of our study was also younger according to older age groups who are more vulnerable to COVID-19-related morbidity and mortality. In conclusion, our study shows that the use of omalizumab does not increase the risk of COVID-19 infection, COVID-19-related pneumonia and COVID-19-related hospitalizations in CSU patients and supports the views that omalizumab can be used safely in patients with CSU during the COVID-19 pandemic.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.01.29.22270077v1 on medRxiv